Ami Fadia
Stock Analyst at Needham
(3.78)
# 782
Out of 4,761 analysts
389
Total ratings
49.42%
Success rate
8.75%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Reiterates: Hold | n/a | $128.60 | - | 27 | Feb 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $52 → $50 | $34.89 | +43.31% | 31 | Feb 19, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $133 → $153 | $137.84 | +11.00% | 11 | Feb 19, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Buy | $133 | $92.31 | +44.09% | 28 | Feb 14, 2025 | |
| BIIB Biogen | Reiterates: Hold | n/a | $140.26 | - | 37 | Feb 13, 2025 | |
| SAGE Sage Therapeutics | Reiterates: Hold | n/a | $7.35 | - | 19 | Feb 12, 2025 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $150 | $76.45 | +96.21% | 8 | Feb 10, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $119.51 | - | 12 | Feb 7, 2025 | |
| IMRX Immuneering | Reiterates: Buy | $12 | $1.81 | +564.82% | 13 | Feb 6, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Buy | $33 | $12.25 | +169.39% | 18 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $11.73 | +172.83% | 16 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $8.57 | +121.83% | 32 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $1.76 | +1,210.54% | 6 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $207 | $135.84 | +52.39% | 26 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $15 | $7.96 | +88.44% | 21 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $85 | $47.42 | +79.25% | 25 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $62 | $41.71 | +48.65% | 20 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $20.04 | +39.76% | 6 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $16 | $0.59 | +2,589.98% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $25.49 | +194.23% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $1.51 | +1,395.02% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $25.27 | +149.31% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $3.31 | +51.06% | 2 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $16.66 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.74 | +1,168.01% | 4 | Jan 3, 2018 |
Intra-Cellular Therapies
Feb 21, 2025
Reiterates: Hold
Price Target: n/a
Current: $128.60
Upside: -
Harmony Biosciences Holdings
Feb 19, 2025
Maintains: Buy
Price Target: $52 → $50
Current: $34.89
Upside: +43.31%
Axsome Therapeutics
Feb 19, 2025
Maintains: Buy
Price Target: $133 → $153
Current: $137.84
Upside: +11.00%
Blueprint Medicines
Feb 14, 2025
Reiterates: Buy
Price Target: $133
Current: $92.31
Upside: +44.09%
Biogen
Feb 13, 2025
Reiterates: Hold
Price Target: n/a
Current: $140.26
Upside: -
Sage Therapeutics
Feb 12, 2025
Reiterates: Hold
Price Target: n/a
Current: $7.35
Upside: -
Praxis Precision Medicines
Feb 10, 2025
Reiterates: Buy
Price Target: $150
Current: $76.45
Upside: +96.21%
Neurocrine Biosciences
Feb 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $119.51
Upside: -
Immuneering
Feb 6, 2025
Reiterates: Buy
Price Target: $12
Current: $1.81
Upside: +564.82%
Day One Biopharmaceuticals
Jan 13, 2025
Reiterates: Buy
Price Target: $33
Current: $12.25
Upside: +169.39%
Jan 13, 2025
Reiterates: Buy
Price Target: $32
Current: $11.73
Upside: +172.83%
Jan 9, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $8.57
Upside: +121.83%
Jan 2, 2025
Reiterates: Buy
Price Target: $23
Current: $1.76
Upside: +1,210.54%
Dec 12, 2024
Reiterates: Buy
Price Target: $207
Current: $135.84
Upside: +52.39%
Dec 11, 2024
Downgrades: Hold
Price Target: $15
Current: $7.96
Upside: +88.44%
Dec 9, 2024
Reiterates: Buy
Price Target: $85
Current: $47.42
Upside: +79.25%
Dec 6, 2024
Maintains: Buy
Price Target: $68 → $62
Current: $41.71
Upside: +48.65%
Nov 7, 2024
Reiterates: Buy
Price Target: $28
Current: $20.04
Upside: +39.76%
Feb 1, 2021
Maintains: Outperform
Price Target: $12 → $16
Current: $0.59
Upside: +2,589.98%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $25.49
Upside: +194.23%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $1.51
Upside: +1,395.02%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $25.27
Upside: +149.31%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $3.31
Upside: +51.06%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $16.66
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.74
Upside: +1,168.01%